CN107753488A - A kind of pharmaceutical composition for treating hypertensive obesity patient and preparation method thereof - Google Patents
A kind of pharmaceutical composition for treating hypertensive obesity patient and preparation method thereof Download PDFInfo
- Publication number
- CN107753488A CN107753488A CN201711016874.6A CN201711016874A CN107753488A CN 107753488 A CN107753488 A CN 107753488A CN 201711016874 A CN201711016874 A CN 201711016874A CN 107753488 A CN107753488 A CN 107753488A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- orlistat
- blocking agent
- alpha receptor
- receptor blocking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Abstract
The present invention relates to a kind of pharmaceutical composition for treating hypertensive obesity patient and preparation method thereof, including alpha receptor blocking agent and orlistat.Orlistat and alpha receptor blocking agent are prepared into pharmaceutical composition by the invention, play orlistat fat-reducing, the purpose of alpha receptor blocking agent medicine decompression, by largely testing discovery, by the pharmaceutical composition that alpha receptor blocking agent and orlistat form in terms for the treatment of hypertensive obesity disease have it is notable the effect of.
Description
Technical field
The present invention relates to a kind of Western medicine compound, more particularly to a kind of pharmaceutical composition for treating hypertensive obesity patient and its
Preparation method.
Background technology
Obesity is a common clinical problem with hypertension, and the research of epidemiology shows, obesity is hypertension
One of important risk factor, the relative risk of hypertension incidence substantially increase with the increase of body mass index, meanwhile, it is fat and
Both hypertension is the important risk factor of cardiovascular disease, and the two simultaneously in the presence of, its hazards more aggravates.According to system
Meter, the incidence of disease of high blood pressure is 10-15%, wherein having 10-40% with fat or overweight.The hair of high blood pressure in overweight people
The fact that raw rate is significantly higher than non-obese person, and this is confirmed by clinical observation.
Hypertensive obesity patient should lose weight, and be depressured again, there is no effectively suffer from for hypertensive obesity in the market
The medicine of person, therefore, finding effective medicine of intervening has very important theory significance and application value.
The content of the invention
In view of the deficiencies in the prior art, the invention provides a kind of pharmaceutical composition for treating hypertensive obesity patient and its
Preparation method, the purpose of fat-reducing and decompression can be reached simultaneously, and it is notable with efficacy of antihypertensive treatment to lose weight, and is expected to turn into clinical treatment
The first-line drug of hypertensive obesity patient.
The technical scheme that the present invention takes is as follows：
One aspect of the present invention provides a kind of pharmaceutical composition for treating hypertensive obesity patient, its effective active composition bag
Include alpha receptor blocking agent and orlistat.
Further, with weight ratio meter, alpha receptor blocking agent：Orlistat=0.1-1:1.
Further, the alpha receptor blocking agent be selected from Bunazosin, Doxazosin, Terazosin, Urapidil or its can
Pharmaceutical salts.
Further, the formulation of described pharmaceutical composition is Duracaps.
Another aspect of the present invention provides a kind of preparation method for the pharmaceutical composition for treating hypertensive obesity patient, by α
Receptor blocking pharmacon and orlistat are prepared into sustained release pellet respectively, then measure alpha receptor blocking agent sustained release pellet and Austria by formula
Li Sita sustained release pellets are prepared into capsule；Wherein, the alpha receptor blocking agent is selected from medicine as described above.
Present invention also offers a kind of above-mentioned pharmaceutical composition answering in treatment hypertensive obesity disease medicament is prepared
With.
Orlistat and alpha receptor blocking agent are prepared into pharmaceutical composition by the invention, are played orlistat and are subtracted
Fertilizer, the purpose of alpha receptor blocking agent medicine decompression, by largely testing discovery, are made up of alpha receptor blocking agent and orlistat
Pharmaceutical composition in terms for the treatment of hypertensive obesity have it is notable the effect of.
Embodiment
Embodiments of the present invention are described in detail below with reference to embodiment, and illustrated embodiment is served only for explaining this hair
It is bright, it is not intended to limit the scope of the present invention.
Embodiment 1
In terms of parts by weight, 30 parts of Bunazosin is taken, 100 parts of orlistat, clinically acceptable auxiliary material is distinguished for use
Bunazosin sustained release pellet and orlistat sustained release pellet are prepared into, is then mixed and made into capsule, produces pharmaceutical composition glue
Capsule.
Embodiment 2
In terms of parts by weight, 50 parts of Bunazosin is taken, 100 parts of orlistat, clinically acceptable auxiliary material is distinguished for use
Bunazosin sustained release pellet and orlistat sustained release pellet are prepared into, is then mixed and made into capsule, produces pharmaceutical composition glue
Capsule.
Embodiment 3
In terms of parts by weight, 30 parts of Doxazosin is taken, 100 parts of orlistat, clinically acceptable auxiliary material is distinguished for use
Doxazosin sustained release pellet and orlistat sustained release pellet are prepared into, is then mixed and made into capsule, produces pharmaceutical composition glue
Capsule.
Embodiment 4
In terms of parts by weight, 50 parts of Doxazosin is taken, 100 parts of orlistat, clinically acceptable auxiliary material is distinguished for use
Doxazosin sustained release pellet and orlistat sustained release pellet are prepared into, is then mixed and made into capsule, produces pharmaceutical composition glue
Capsule.
Comparative example 1
In terms of parts by weight, 30 parts of Bunazosin is taken, clinically acceptable auxiliary material is prepared into Bunazosin sustained release for use
Micropill, capsule is then made, produces medicament capsule.
Comparative example 2
In terms of parts by weight, 30 parts of Doxazosin is taken, clinically acceptable auxiliary material is prepared into Doxazosin sustained release for use
Micropill, capsule is then made, produces medicament capsule.
Comparative example 3
In terms of parts by weight, 100 parts of orlistat is taken, clinically acceptable auxiliary material is prepared into orlistat sustained release for use
Micropill, capsule is then made, produces medicament capsule.
Experimental example
350 hypertensive obesity patients are randomly divided into 7 groups, wherein first group of drug regimen for taking the preparation of embodiment 1
Composite capsule, second group of medicament composition capsule for taking the preparation of embodiment 2, the 3rd group of drug regimen for taking the preparation of embodiment 3
Composite capsule, the 4th group of medicament composition capsule for taking the preparation of embodiment 4, the 5th group of medicament capsule for taking the preparation of comparative example 1,
The 6th group of medicament capsule for taking the preparation of comparative example 2, the 7th group of medicament capsule for taking the preparation of comparative example 3, each patient are daily
Taking dose it is identical, be 2, after taking 12 months, the body weight and blood pressure of patient measured, as a result shown in table 1：
Table 1
As seen from Table 1, fat and hypertension can be treated simultaneously using the pharmaceutical composition of the present invention, and compared to simple
With depressor or slimming drugs, the present invention shares depressor and slimming drugs, more preferable to the effect losing weight and be depressured.
The foregoing is only presently preferred embodiments of the present invention, be not intended to limit the invention, it is all the present invention spirit and
Within principle, any modification, equivalent substitution and improvements made etc., it should be included in the scope of the protection.
Claims (6)
1. a kind of pharmaceutical composition for treating hypertensive obesity patient, it is characterised in that its effective active composition hinders including α acceptors
Disconnected agent and orlistat.
2. the pharmaceutical composition for the treatment of hypertensive obesity patient according to claim 1, it is characterised in that with weight ratio
Meter, alpha receptor blocking agent：Orlistat=0.1-1:1.
3. the pharmaceutical composition for the treatment of hypertensive obesity patient according to claim 1, it is characterised in that the α acceptors
Blocking agent is selected from Bunazosin, Doxazosin, Terazosin, Urapidil or its officinal salt.
4. the pharmaceutical composition of the treatment hypertensive obesity patient according to claim any one of 1-3, it is characterised in that institute
The formulation for stating pharmaceutical composition is Duracaps.
5. a kind of preparation method for the pharmaceutical composition for treating hypertensive obesity patient, it is characterised in that first by alpha receptor blocking agent
Sustained release pellet is prepared into respectively with orlistat, and then the formula as described in claim 2 measures alpha receptor blocking agent sustained release pellet
Capsule is prepared into orlistat sustained release pellet；Wherein, the alpha receptor blocking agent is selected from the medicine described in claim 3.
6. a kind of pharmaceutical composition as described in claim any one of 1-4 is in treatment hypertensive obesity disease medicament is prepared
Using.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711016874.6A CN107753488A (en) | 2017-10-26 | 2017-10-26 | A kind of pharmaceutical composition for treating hypertensive obesity patient and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711016874.6A CN107753488A (en) | 2017-10-26 | 2017-10-26 | A kind of pharmaceutical composition for treating hypertensive obesity patient and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107753488A true CN107753488A (en) | 2018-03-06 |
Family
ID=61270611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711016874.6A Withdrawn CN107753488A (en) | 2017-10-26 | 2017-10-26 | A kind of pharmaceutical composition for treating hypertensive obesity patient and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107753488A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1686549A (en) * | 2005-05-08 | 2005-10-26 | 广州市施柏医药科技有限公司 | Medicinal composition for treating high blood pressure |
| CN105233288A (en) * | 2015-09-28 | 2016-01-13 | 青岛云天生物技术有限公司 | Pharmaceutical composition for treatment or prevention of obesity-related hypertension and usage of pharmaceutical composition for treatment or prevention of obesity-related hypertension |
| CN105343056A (en) * | 2015-10-09 | 2016-02-24 | 青岛云天生物技术有限公司 | Oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application |
-
2017
- 2017-10-26 CN CN201711016874.6A patent/CN107753488A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1686549A (en) * | 2005-05-08 | 2005-10-26 | 广州市施柏医药科技有限公司 | Medicinal composition for treating high blood pressure |
| CN105233288A (en) * | 2015-09-28 | 2016-01-13 | 青岛云天生物技术有限公司 | Pharmaceutical composition for treatment or prevention of obesity-related hypertension and usage of pharmaceutical composition for treatment or prevention of obesity-related hypertension |
| CN105343056A (en) * | 2015-10-09 | 2016-02-24 | 青岛云天生物技术有限公司 | Oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109985237A (en) | A kind of pharmaceutical composition and its application for treating colorectal cancer | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN107753488A (en) | A kind of pharmaceutical composition for treating hypertensive obesity patient and preparation method thereof | |
| CN103028093B (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary emphysema and preparation method of traditional Chinese medicine composition | |
| CN102698189B (en) | Chinese medicinal composition and preparation with function of treating helicobacter pylori in stomach and preparation method thereof | |
| CN105213822B (en) | A kind of Chinese medicine composition and its application treated phlegm wet and stop up Sheng type essential hypertension | |
| CN108114047A (en) | A kind of Chinese medicine composition for treating reflux esophagitis | |
| CN105213991A (en) | Be used for the treatment of the Chinese medicine composition of gastroesophageal reflux disease | |
| CN107951940B (en) | Blood pressure lowering medicine composition | |
| CN102327304B (en) | Drug for preventing and controlling chronic mountain sickness and preparation method thereof | |
| CN107496558B (en) | Composition for treating cough and application thereof | |
| CN107669673A (en) | A kind of medicine for treating obesity-related hypertension patient and preparation method thereof | |
| CN104127550A (en) | Medicine for treating chemoradiotherapy-induced thrombocytopenia and preparation method thereof | |
| CN107753471A (en) | A kind of pharmaceutical composition for treating obesity-related hypertension patient and preparation method thereof | |
| CN104922383A (en) | Composition capable of improving cardiovascular and cerebrovascular diseases and curing neck-shoulder pain | |
| CN106389999B (en) | Traditional Chinese medicine composition for relieving drunkenness and application thereof | |
| CN106177269A (en) | The pharmaceutical composition of quick curing oral keritonocytes, preparation method and application | |
| CN100559971C (en) | A kind of enhancing body immunity, oxidation resistance functional form health food | |
| CN103417827B (en) | Oral traditional Chinese medicine for treating chronic bronchitis and preparation method thereof | |
| JP2018076312A (en) | Pharmaceutical composition containing acetaminophen, isopropylantipyrine and ginger-derived components | |
| CN102366537A (en) | Traditional Chinese medicine preparation for treating cough caused by lung dryness and preparation method thereof | |
| CN102283832B (en) | Medicinal composition for preventing or treating hypertensive obese patient and application thereof | |
| CN107753482A (en) | A kind of drug compound preparation for treating obesity-related hypertension patient and preparation method thereof | |
| CN107596375A (en) | A kind of drug compound preparation for treating hypertensive obesity patient and preparation method thereof | |
| CN101129747A (en) | Pill of pinellia tuber for relieving cough |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180306 |